Arsenic and ATRA for new APL patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be newly diagnosed with APL (a type of leukemia) and confirmed by genetic testing
- Age between 18 and 75 years old
- Good liver and kidney function (based on blood tests)
- Women must be postmenopausal, have had surgery to prevent pregnancy, use highly effective birth control, or have a partner who had a vasectomy
- No other active cancer or serious heart, lung, or liver conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing an oral (pill) form of arsenic trioxide to the standard IV (drip) form. If you have already completed initial therapy for your type of leukemia and are in remission, this study could help you take your medicine as a pill instead of through a needle.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
This study looks at how well first-time treatment with ATO plus ATRA works in adults with acute promyelocytic leukemia (APL). It mainly checks treatment results in real life, including whether patients reach “molecular remission” (very deep disease control).
Hear when a new Acute Promyelocytic Leukemia (APL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.